ArticleFrontiers in oncology2025

Durable clinical benefit from gefitinib plus bevacizumab in a non-small cell lung cancer patient with an acquired C797S mutation following osimertinib treatment: a case report and literature review.

Yuping Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.